1085 related articles for article (PubMed ID: 26258846)
1. Genomic spectra of biliary tract cancer.
Nakamura H; Arai Y; Totoki Y; Shirota T; Elzawahry A; Kato M; Hama N; Hosoda F; Urushidate T; Ohashi S; Hiraoka N; Ojima H; Shimada K; Okusaka T; Kosuge T; Miyagawa S; Shibata T
Nat Genet; 2015 Sep; 47(9):1003-10. PubMed ID: 26258846
[TBL] [Abstract][Full Text] [Related]
2. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
3. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
4. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
6. E74-Like Factor 3 Is a Key Regulator of Epithelial Integrity and Immune Response Genes in Biliary Tract Cancer.
Suzuki M; Saito-Adachi M; Arai Y; Fujiwara Y; Takai E; Shibata S; Seki M; Rokutan H; Maeda D; Horie M; Suzuki Y; Shibata T; Kiyono T; Yachida S
Cancer Res; 2021 Jan; 81(2):489-500. PubMed ID: 33293429
[TBL] [Abstract][Full Text] [Related]
7. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
[TBL] [Abstract][Full Text] [Related]
8. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
9. Biliary tract cancer prognostic and predictive genomics.
Mondaca S; Nervi B; Pinto M; Abou-Alfa GK
Chin Clin Oncol; 2019 Aug; 8(4):42. PubMed ID: 31431036
[TBL] [Abstract][Full Text] [Related]
10. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H; Xu Y; Gao W; Li M; He J; Deng X; Xing W
Front Oncol; 2022; 12():930611. PubMed ID: 36072793
[TBL] [Abstract][Full Text] [Related]
12. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract.
Roos E; Soer EC; Klompmaker S; Meijer LL; Besselink MG; Giovannetti E; Heger M; Kazemier G; Klümpen HJ; Takkenberg RB; Wilmink H; Würdinger T; Dijk F; van Gulik TM; Verheij J; van de Vijver MJ
Crit Rev Oncol Hematol; 2019 Aug; 140():8-16. PubMed ID: 31158800
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
14. Molecular-driven treatment for biliary tract cancer: the promising turning point.
Persano M; Puzzoni M; Ziranu P; Pusceddu V; Lai E; Pretta A; Donisi C; Pinna G; Spanu D; Cimbro E; Parrino A; Liscia N; Mariani S; Dubois M; Migliari M; Scartozzi M
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1253-1264. PubMed ID: 34551663
[TBL] [Abstract][Full Text] [Related]
15. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
16. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
[TBL] [Abstract][Full Text] [Related]
17. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D; Ferté C
Eur J Cancer; 2017 Aug; 81():161-173. PubMed ID: 28628842
[TBL] [Abstract][Full Text] [Related]
18. Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients.
Conci S; Ruzzenente A; Simbolo M; Bagante F; Rusev B; Isa G; Lawlor RT; Pedrazzani C; Iacono C; Guglielmi A; Scarpa A
Updates Surg; 2020 Mar; 72(1):119-128. PubMed ID: 32020551
[TBL] [Abstract][Full Text] [Related]
19. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study).
Maruki Y; Morizane C; Arai Y; Ikeda M; Ueno M; Ioka T; Naganuma A; Furukawa M; Mizuno N; Uwagawa T; Takahara N; Kanai M; Asagi A; Shimizu S; Miyamoto A; Yukisawa S; Kadokura M; Kojima Y; Furuse J; Nakajima TE; Sudo K; Kobayashi N; Hama N; Yamanaka T; Shibata T; Okusaka T
J Gastroenterol; 2021 Mar; 56(3):250-260. PubMed ID: 33106918
[TBL] [Abstract][Full Text] [Related]
20. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
